

*Citation for published version:*

Thitilertdecha, P, Rowan, MG & Guy, RH 2015, 'Topical formulation and dermal delivery of active phenolic compounds in the Thai medicinal plant - *Clerodendrum petasites* S. Moore', *International Journal of Pharmaceutics*, vol. 478, no. 1, pp. 39-45. <https://doi.org/10.1016/j.ijpharm.2014.11.004>

*DOI:*

[10.1016/j.ijpharm.2014.11.004](https://doi.org/10.1016/j.ijpharm.2014.11.004)

*Publication date:*

2015

*Document Version*

Peer reviewed version

[Link to publication](https://doi.org/10.1016/j.ijpharm.2014.11.004)

**University of Bath**

## **Alternative formats**

If you require this document in an alternative format, please contact:  
[openaccess@bath.ac.uk](mailto:openaccess@bath.ac.uk)

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

**Topical formulation and dermal delivery of active phenolic compounds in the Thai medicinal plant - *Clerodendrum petasites* S. Moore**

Premrutai Thitilertdecha<sup>1,2,\*</sup>, Michael G Rowan<sup>1</sup>, Richard H Guy<sup>1</sup>

<sup>1</sup>University of Bath, Department of Pharmacy & Pharmacology, Bath, BA2 7AY, England.

<sup>2</sup>Center of Applied Thai Traditional Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2, Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand.

\*Tel: +6624198906-8; Fax: +6624198818

E-mail address: [premrutai@gmail.com](mailto:premrutai@gmail.com)

## Abstract

**Purpose:** To develop topical formulations of *Clerodendrum petasites* S. Moore (CP), and to optimise the skin permeability and topical bioavailability of the active phenolic compounds therein.

**Methods:** The skin uptake and delivery of active compounds from two formulations, an oil-in-water cream and a lotion (both containing 10% w/w CP extracts), were examined (a) *in vitro* using pig skin, and (b) *in vivo* in human volunteers. Stratum corneum (SC) was collected by tape stripping and the compounds were detected and quantified by high performance liquid chromatography coupled with either mass spectrometry (HPLC-MS) or ultraviolet and photodiode array (HPLC-UV-PDA) detection.

**Results:** From the *in vitro* results, vanillic acid, verbascoside, nepetin and hispidulin, were chosen as potential phenolic actives for topical delivery optimisation from the formulations. *In vivo*, vanillic acid, nepetin and hispidulin were appreciably taken up into the SC within 6 hours, while verbascoside did not penetrate beyond the most superficial layers. No significant differences in delivery were observed between the two formulations, both of which were well tolerated.

**Conclusions:** The detected topical absorption of hispidulin, nepetin, and vanillic acid, from the cream and lotion vehicles investigated, suggest that these compounds are potentially active compounds in Thai traditional medicine for the treatment of a wide range of skin diseases.

**Keywords:** *Clerodendrum petasites* S. Moore, hispidulin, skin permeation, topical bioavailability, mass spectrometry.

**Chemical compounds:** Vanillic acid (PubChem CID: 8468); verbascoside (PubChem CID: 5281800); nepetin (PubChem CID: 5317284); hispidulin (PubChem CID: 5281628).

**Abbreviations:** CP, *Clerodendrum petasites* S. Moore; HPLC, high performance liquid chromatography; MS, mass spectrometry; PDA, photodiode array; SC, stratum corneum; TEWL, transepidermal water loss;  $K_{SC,V}$ , SC-vehicle partition coefficients; LOQ, limit of quantification.

## Introduction

*Clerodendrum petasites* S. Moore (Lamiaceae, English name: One Root Plant, Thai name: Thao-Yaai-Mom) is commonly found in the middle, north-eastern and southern parts of Thailand. It is extensively prepared as a tea, alcoholic extract, cigarette, or powder for oral administration to treat asthma (Hazekamp *et al.*, 2001; Panthong *et al.*, 2003; Panthong *et al.*, 1986), inflammation (Panthong *et al.*, 1986), fever, cough and vomiting (Panthong *et al.*, 2003; Thai traditional medical textbook: Paet-Ta-Ya-Saat-Song-Kror 2007) (S. Tungjitaruen, pers. comm., 2011). For topical use, the traditional dosage form is a poultice to treat skin diseases, such as rash, abscess, urticaria, snakebites and insect bites (Panthong *et al.*, 2003; Pongboonrot, 1965; Thai traditional medical textbook: Paet-Ta-Ya-Saat-Song-Kror 2007) (T. Tipcharoentham, pers. comm., 2011; S. Tungjitaruen, pers. comm., 2011). Alcohol, especially Thai rice whisky, is often used as a dispersing vehicle in many formulations before application. At present, only the plant itself and powders therefrom are found on the market with poor reliability and reproducibility with respect to the active ingredients. These forms are also inconvenient to use and transport. The nature of the active species remain poorly characterized (Hazekamp *et al.*, 2001; Klaiklay, 2009; Singharachai *et al.*, 2011; Thongchai *et al.*, 2007) and there is no information concerning the topical bioavailability of active species from this plant.

A preliminary study, reported elsewhere (Thitilertdecha *et al.*, 2014), identified eleven phenolic compounds, vanillic acid, 4-coumaric acid, ferulic acid, verbascoside, nepetin, luteolin, chrysin, naringenin, hesperetin, apigenin, and hispidulin, in an ethanolic (80%) extract of the plant, predicted their maximum skin fluxes ( $J_{\max}$ ) and measured skin absorption *in vitro* from a 50% w/w CP paste and a 50 mg·mL<sup>-1</sup> CP solution. In the present study, suitable dosage forms for topical delivery to the skin were developed and optimised, and the topical bioavailability of the active substances was determined *in vivo* in human volunteers.

## 59    **Materials and methods**

### 60    1    Plant materials

61    Dried samples of CP were obtained from the Ayurved Siriraj Manufacturing Unit of Herbal Medicines  
62    and Products, Center of Applied Thai Traditional Medicine (CATTM), Faculty of Medicine Siriraj  
63    Hospital, Mahidol University, Thailand. An extract of powdered plant was produced by maceration  
64    using 80% ethanol and subsequently lyophilized to dryness (Alpha 2-4 LSC, Martin Christ Company,  
65    Germany). Prior to use, the extracts were kept separately in light protective and airtight containers  
66    and stored in a desiccator at room temperature. Batch-to-batch consistency of the ethanolic extracts  
67    was confirmed by quantification of phenolic constituents as described previously (Thitilertdecha *et*  
68    *al.*, 2014).

### 69    2    Chemicals and reagents

70    Vanillic acid (Fluka Analytical, China), verbascoside, nepetin (Extrasynthese, France), and hispidulin  
71    (Tocris Bioscience, UK), were of analytical grade.

72    Mobile phases for HPLC-MS and HPLC-PDA consisted of chromatography grade acetonitrile (Fisher  
73    Scientific, UK), deionized water (Millipore, MA, USA) and MS grade acetic acid (Fluka Analytical,  
74    Germany). Tris (hydroxymethyl) aminomethane hydrochloride (Tris-HCl, Acros Organics, USA), tris  
75    (hydroxymethyl) aminomethane (Trizma® base, Sigma-Aldrich, USA), methanol, and ethanol (Sigma-  
76    Aldrich, USA) were of analytical grade. Acetone was laboratory grade.

77    Excipients of the topical formulations were propyl paraben (propyl 4-hydroxybenzoate), stearyl  
78    alcohol (1-octadecanol), Tween 60 (polyethylene glycol sorbitan monostearate), Span 60 (sorbitan  
79    monooleate), glycerol, mineral oil, and triethanolamine (TEA) (Sigma-Aldrich, USA), methyl  
80    paraben (methyl 4-hydroxybenzoate) and cetyl alcohol (Fluka Analytical, Germany), butylated  
81    hydroxytoluene (BHT) (SAFC, Germany), propylene glycol (Acros Organics, UK), glycerol

monostearate-self emulsifier (GMS-SE) and Carbopol ultrez 21 (acrylates/C10-30 alkyl acrylate crosspolymer (The Lubrizol Corporation, USA).

### 3 Skin for the *in vitro* permeation study

Fresh porcine abdominal skin was obtained from B&J Pigs Ltd, Somerset, UK. Excess hair was carefully trimmed using scissors. After cleaning with running cold water, the skin was dermatomed (Zimmer electric dermatome, Oklahoma, USA) to a nominal thickness of 750 µm. The dermatomed skin was sealed in a plastic bag and stored at -20°C until use.

### 4 Human subjects

Six healthy volunteers aged between 25 and 31 years (4 females and 2 males), with no history of skin disease, no visible skin abnormalities and no prior skin treatment in the preceding 4 weeks, participated in the study. Written informed consent was obtained from each subject before the study, which was approved by the University of Bath Ethics Committee.

### 5 Cream and lotion formulations

Excipients of the cream and lotion are in Table I. They were formulated and then stored in a light-protective and airtight container at 4°C.

**Table I:** Excipients of cream and lotion formulations.

Excipient	Quantity (% w/w)			
	10% CP cream	Control cream	10% CP lotion	Control lotion
<i>C. petasites</i> (dried ethanolic extracts)	10	-	10	-
GMS-SE	5	5	1	1
Cetyl alcohol	5	5	1.5	1.5
Stearyl alcohol	2.5	2.5	-	-
Mineral oil	15	15	15	15
Tween 60	4	4	4	4
Span 60	1	1	1	1
Carbopol ultrez (2% w/w stock gel)*	3	3	3	3
Propylene glycol	4	4	3	3
Glycerol	3	3	-	-
Concentrated paraben**	1% v/w	1% v/w	1% v/w	1% v/w
BHT	0.02	0.02	0.02	0.02
Purified water qs. to	100	100	100	100

\* Pre-preparation required before formulating cream and lotion.

\*\* A preservative mixture of methyl paraben (10 g) and propyl paraben (2 g) in propylene glycol (100 mL).

## 6 Analytical methods

### 6.1 High performance liquid chromatography coupled with mass spectrometry (HPLC-MS)

HPLC-MS was performed on a Shimadzu HPLC-2010A HT system (Shimadzu Corp., Kyoto, Japan) consisting of an autosampler, vacuum degasser, and UV detector operating at 260 and 330 nm.

The HPLC was interfaced to a Shimadzu MS-2010EV system (Shimadzu Corp., Kyoto, Japan) with a dual source of electrospray ionization and atmospheric pressure chemical ionization (ESI/APCI, DUIS-2010, Japan). Ionization was achieved in both negative- and positive-ion-modes with the detector voltage set at 1.5 kV. Nitrogen was used as a nebulising gas, heated to 480°C and delivered at a flow rate of 1.5 L·min<sup>-1</sup>. MS signals collected in the single ion-monitoring (SIM) mode were used for quantification of individual compounds.

The column used was a Dionex Acclaim® 120 (C18, 5 µm, 150 x 4.6 mm i.d.). The mobile phase was a combination of acetonitrile (A) and 0.1% aqueous acetic acid (v/v, B) with an optimized gradient system of 20% A for 9 min, 20-60% A for 6 min, 60% A for 5 min, 60-95% A for 10 min, 95% A for 5 min and 20% A for 25 min. The injection volume was 20 µL and the flow rate was 0.5 mL·min<sup>-1</sup>. The column temperature was maintained at 35°C throughout the analysis. All data acquired were processed by the LabSolutions LCMS Software (Shimadzu Corp., Kyoto, Japan).

### 6.2 HPLC coupled to ultraviolet and photodiode array detection (HPLC-UV-PDA)

HPLC-UV-PDA was carried out using an ASI-100 automated sample injector, thermostatted column compartment TCC-100 and PDA-100 photodiode array detector (Dionex® Ltd., UK). The UV detection wavelengths were 260 and 330 nm for quantification and the maximum wavelengths ( $\lambda_{\max}$ ) of each peak were confirmed by a wavelength scan from 240 to 360 nm.

A HiQ Sil C18 HS column (C18, 5 µm, 150 x 4.6 mm i.d., Kyatech, Japan) was used at a temperature of 35°C. The HPLC-PDA conditions differed only slightly from those optimized for HPLC-MS. Acetonitrile (A) and a mixture of 0.1% aqueous acetic acid and acetonitrile (v/v, 80:20, B) were combined as the

mobile phase in a gradient system of 0% A for 9 min, 0-50% A for 6 min, 50% A for 5 min, 50-94% A for 10 min, 94% A for 5 min and 0% A for 25 min with a flow rate of 0.5 mL·min<sup>-1</sup>. 20 µL of each sample was injected. Chromatograms were interpreted with Chromeleon software (Dionex® Ltd., UK). Retention times ( $t_R$ ) and UV peak detection using HPLC-PDA were compared with those using HPLC-MS.

## 7 *In vitro* skin penetration experiments

The skin permeation of compounds in the plant extracts was determined in vertical, glass Franz diffusion cells (PermeGear, Inc., Bethlehem, PA, USA). The exposed membrane surface area was 1.77 cm<sup>2</sup> and the receptor solution was 7.5 mL of a mixture of ethanol and 5 mM Tris buffer in ratio of 1:4 v/v, at pH 7.3 (i.e., slightly less than 7.4 due to the presence of ethanol). Frozen dermatomed pig abdominal skin was thawed for 30 minutes before use and examined visually for punctures or defects. The skin was stripped with one adhesive tape (3.5 cm x 3.5 cm, Scotch book tape, 3M, MN, USA) to remove SC disjunctum before being mounted into the Franz cell. After temperature equilibration at 37°C, approximately 0.2 g of the formulations was applied to the skin surface and occluded with Parafilm™ (Bemis Company, Inc., Neenah, WI). After 6 hours, the whole receptor solution volume was removed and stored at 4°C under light protection before quantitative analysis. The skin was subsequently taken out of the Franz cell and the remaining formulation was removed with an isopropyl alcohol swab (70% isopropyl alcohol; Sterets®, Medlock Medical Ltd., UK). The skin was then pinned to a polystyrene board and left to air dry for 3 hours. A template with a circular aperture (1.4 cm diameter, Scotch book tape, 3M, MN, USA) was positioned over the treated area before stripping the SC using tapes. Six replicates were performed with each formulation.

## 8 *In vivo* skin penetration experiments


The passive diffusion of constituents of the two plant extract formulations into the SC of healthy volunteers was studied over 2 days. On day 1, the first formulation was applied to one arm; on day 2, the second formulation was applied to the other. The ventral forearms were cleaned with an



149 alcohol wipe and the subject was acclimatized to the treatment venue for 30 minutes. Four skin sites  
150 (3 treated + 1 blank, control) were delineated on each arm at least 4 cm above the wrist and a  
151 minimum of 4 cm below the elbow. Each treatment site (6 cm<sup>2</sup> in area, Figure 1) was demarcated  
152 with a rectangular frame cut from a self-adhesive foam (1.57 mm in thickness; 3M, USA) and applied  
153 to the ventral forearm with the long dimension oriented across the forearm. One tape strip was  
154 discarded before drug application to remove SC disjunctum. Good contact between tape and skin  
155 was ensured by running a weighted roller (6 cm wide, 140 g cm<sup>-2</sup>) over the tape several times before  
156 its removal. A fingertip cut from a laboratory glove (nitrile and powder-free glove; Kimtech, UK) was  
157 used to distribute the cream/lotion over the demarcated area. The sites were treated at 45-minute  
158 intervals. Approximately 0.2 g of the product (containing 10% w/w CP extracts) was applied to sites  
159 1-3, while the blank (cream/lotion base without CP) was applied to site 4. The actual amount applied  
160 was determined by weighing the fingertip before and after drug application. All sites were occluded  
161 by covering the foam frame with Parafilm™ secured to the skin with a self-adhesive fabric dressing  
162 (Mefix®, SCA Molnlycke Ltd., Sweden). The drug application time was 6 hours.

163 At the end of the experiment, the dressing, Parafilm™ and foam frame were removed. Excess  
164 cream/lotion was gently wiped away with tissue (Fort James Ltd., UK), and then swabbed three  
165 times with alcohol wipes. The skin was finally left to air dry for 1 minute before a new thin foam  
166 frame (dimension of the cut out inside are 1.5 cm x 2 cm, 0.75 mm in thickness; 3M, USA) was placed  
167 over each cleaned site in the same position as the original frame (Figure 1). Subsequently, the tape  
168 stripping procedures were commenced.

169



**Figure 1:** Illustration of drug application and tape strip area (adapted from reference (N'Dri-Stempfer *et al.*, 2009)).

## 9 Tape stripping and tape extraction

Tape stripping was performed at the end of the *in vitro* and *in vivo* percutaneous experiments. The stripped area was delineated by the templates. First, transepidermal water loss (TEWL) was measured (AquaFlux® evaporimeter, Biox System Ltd., UK) to obtain an initial value. An adhesive tape strip (2.5 cm x 2.5 cm; Permacel J-LAR®) was applied to the skin and pressed firmly down using the weighted roller. The tape was removed quickly from the skin and TEWL was measured again. The procedure was repeated until TEWL reached 4 times the initial value or when 30 strips had been taken.

The mass of skin removed on each tape was determined by weighing the tapes on a microbalance (Sartorius model SE2-F, Sartorius AG, Germany), before and after application to the skin. Before weighing, the tapes were stored at room temperature for at least 12 hours and static electricity was discharged (R50 discharging bar and ES50 power supply, Eltex Elektrostatik GmbH, Weil am Rhein, Germany).

After weighing, the tapes were grouped for methanol extraction. The first and second tapes were individually analysed, while the remaining tape strips were combined into groups of 2-4 tapes depending on the total number collected in each experiment. Groups containing 1-2 tapes were extracted with 1 mL of methanol, those with 3-4 tapes were extracted into 1.5 mL. Extraction involved shaking overnight (IKA HS 260 Basic shaker, IKA® Werke GmbH & Co., KG, Germany). The

191 extracted solutions were then filtered through a 0.45 µm nylon membrane, and either directly  
192 injected, or concentrated by freeze-drying before injection into an HPLC-MS or HPLC-PDA. If not  
193 processed at once, the samples were freeze-dried and stored at 4°C before analysis.

#### 194 10 Statistical analysis

195 All statistical analyses were performed using GraphPad Prism® version 5 (GraphPad Software Inc.,  
196 CA, USA). Calibration curves were assessed by linear regression. Datasets were expressed as mean ±  
197 SD (standard deviation) and compared for statistical significance at  $P \leq 0.05$  with two-way ANOVA  
198 and Bonferroni post-tests.

199

## Results

### 1 *In vitro* percutaneous absorption of CP constituents from a cream and a lotion

On the basis of preliminary results (Thitilertdech et al., 2014), four compounds, vanillic acid, verbascoside, nepetin and hispidulin, all known to be present in the CP extract, were selected to monitor and compare the performance of the two formulations.

Equivalent sets of sample and control experiments were conducted with a 6-hour application to allow comparison with the results of *in vivo* studies carried out in human volunteers.

**Table II:** Quantities per unit area (and % penetration<sup>a</sup>) of vanillic acid, verbascoside, nepetin and hispidulin detected in SC and in the receptor solution after 6 hours (average  $\pm$  SD, 6 replicates).

Compound	10% w/w CP cream			10% w/w CP lotion		
	Quantity (nmol·cm <sup>-2</sup> )		% penetration	Quantity (nmol·cm <sup>-2</sup> )		% penetration
	In SC	In receptor		In SC	In receptor	
Vanillic acid	0.6 $\pm$ 0.3	0.6 $\pm$ 0.5	2.1 $\pm$ 1.5	0.6 $\pm$ 0.2	0.4 $\pm$ 0.3	1.3 $\pm$ 0.9
Verbascoside	0.3 $\pm$ 0.02 <sup>b</sup>	-	-	0.5 $\pm$ 0.03 <sup>b</sup>	-	-
Nepetin	0.8 $\pm$ 0.6	0.1 $\pm$ 0.02	0.1 $\pm$ 0.01	0.9 $\pm$ 0.6	0.1 $\pm$ 0.03	0.1 $\pm$ 0.02
Hispidulin	3.0 $\pm$ 0.4	1.1 $\pm$ 0.8	0.24 $\pm$ 0.19	2.4 $\pm$ 0.4	0.7 $\pm$ 0.3	0.2 $\pm$ 0.1

a = Values were determined from the ratio of the cumulative amount of compound in the receptor solution to its original content in the formulation applied (calculated from the quantities of the compounds in a dried ethanolic extract, the amount of the dried extract used in the formulation, and the amount of the formulation applied).

b = only 3 replicates were measurable.

All compounds except verbascoside were delivered from both cream and lotion vehicles and were detected in the receptor phase after 6 hours (Table II). Results from tape-stripping (Table II) were consistent with these findings. Vanillic acid and hispidulin were taken up into the SC and crossed the skin well. Verbascoside was only found in the SC and was not percutaneously absorbed. Little difference was observed between the two formulations.

### 2 *In vivo* SC uptake of CP constituents from a cream and a lotion

Cumulative amounts of vanillic acid, nepetin and hispidulin taken up into the SC of the individual volunteers from the cream and lotion are presented in Table III. Transport of hispidulin from the cream (1 nmol·cm<sup>-2</sup>) was approximately double that of nepetin and vanillic acid (0.4, and 0.3

nmol·cm<sup>-2</sup>, respectively). The penetration of these three compounds from the lotion was similar to those from the cream. Verbascoside was not detectable in the SC following application of either the cream or the lotion. Reproducibility was good and the robustness of the *in vivo* methodology was demonstrated by low inter-subject variability: CVs were less than 29% for hispidulin, 44% for vanillic acid, and 55% for nepetin from both formulations.

Table III: Amounts of vanillic acid, verbascoside, nepetin and hispidulin taken up into the SC after a 6-hour application of a cream and a lotion to human volunteers.

Volunteer number	Amount in SC 6-hour post application of <b>10% w/w CP cream</b> (average $\pm$ SD, nmol·cm <sup>-2</sup> , n=3)			
	Vanillic acid	Verbascoside	Nepetin	Hispidulin
1	0.3 $\pm$ 0.1	-	0.4 $\pm$ 0.1	0.7 $\pm$ 0.1
2	0.3 $\pm$ 0.1	-	0.5 $\pm$ 0.2	1.1 $\pm$ 0.1
3	0.4 $\pm$ 0.1	-	0.6 $\pm$ 0.1	1.3 $\pm$ 0.2
4	0.2 $\pm$ 0.02	-	0.6 $\pm$ 0.003	0.9 $\pm$ 0.03
5	0.2 $\pm$ 0.04	-	0.6 $\pm$ 0.1	0.8 $\pm$ 0.1
6	0.6 $\pm$ 0.1 <sup>a</sup>	-	0.1 $\pm$ 0.01 <sup>a</sup>	1.1 $\pm$ 0.1 <sup>a</sup>
<b>Average</b>	<b>0.3 <math>\pm</math> 0.1</b>	-	<b>0.4 <math>\pm</math> 0.2</b>	<b>1.0 <math>\pm</math> 0.2</b>
<b>%RSD</b>	<b>43.1</b>	-	<b>48.5</b>	<b>23.1</b>

<sup>a</sup>Measured with MS detection.


Volunteer number	Amount in SC 6-hour post application of <b>10% w/w CP lotion</b> (average $\pm$ SD, nmol·cm <sup>-2</sup> , n=3)			
	Vanillic acid	Verbascoside	Nepetin	Hispidulin
1	0.5 $\pm$ 0.1	-	0.4 $\pm$ 0.02	0.7 $\pm$ 0.2
2	0.4 $\pm$ 0.1	-	0.6 $\pm$ 0.1	1.2 $\pm$ 0.2
3	0.4 $\pm$ 0.04	-	0.6 $\pm$ 0.2	1.1 $\pm$ 0.1
4	0.2 $\pm$ 0.03	-	0.6 $\pm$ 0.1	0.9 $\pm$ 0.1
5	0.3 $\pm$ 0.1 <sup>a</sup>	-	0.4 $\pm$ 0.3 <sup>a</sup>	0.6 $\pm$ 0.1 <sup>a</sup>
6	0.5 $\pm$ 0.1 <sup>b</sup>	-	0.05 $\pm$ 0.02 <sup>b</sup>	0.8 $\pm$ 0.2 <sup>b</sup>
<b>Average</b>	<b>0.4 <math>\pm</math> 0.1</b>	-	<b>0.5 <math>\pm</math> 0.3</b>	<b>0.9 <math>\pm</math> 0.2</b>
<b>%RSD</b>	<b>29.0</b>	-	<b>54.9</b>	<b>28.5</b>

<sup>a</sup>Two sites were measured with UV detection, a third with MS; b = 3 sites were measured with MS detection.

When nepetin was detected by MS in volunteer 6, the level observed was small. While there should be little or no difference between the PDA and MS assays, it is possible that the PDA peak for nepetin was subject to interference by other compounds in the plant extract with a similar retention time (e.g., luteolin). It is possible, therefore, that the nepetin quantities found in volunteers 1-5 using PDA may over-estimate the actual amounts present in the SC. In contrast, no interfering peaks with those of vanillic acid and hispidulin were apparent.

Figure 2 compares in 1 subject the SC concentration versus depth profiles of vanillic acid, nepetin, and hispidulin, respectively, from the two formulations after a 6-hour application. Vanillic acid

showed a more or less constant low concentration throughout the SC. Concentration-depth profiles of nepetin and hispidulin were similar to those reported previously for other, unrelated compounds (Alberti *et al.*, 2001; Herkenne *et al.*, 2007; Wagner *et al.*, 2000). There were consistent profiles observed for the 6 volunteers (see the Supplementary Data) except for nepetin in volunteer 6 when the MS assay was used.



**Figure 2:** SC concentration versus depth profiles of vanillic acid, nepetin, and hispidulin in 1 subject after a 6-hour application of 10% w/w CP cream (panel A) and 10% w/w CP lotion (panel B).

## Discussion

Preliminary *in vitro* percutaneous penetration studies determined the topical absorption of the principal phenolic actives in CP (Thitilertdecha *et al.*, 2014). Vanillic acid, nepetin and hispidulin were the three compounds showing the most substantial absorption and thus were the likeliest candidates for eliciting CP's antimicrobial (Delaquis *et al.*, 2005; Sultana and Afolayan, 2007), anti-inflammatory (Clavin *et al.*, 2007; Gil *et al.*, 1994; Kim *et al.*, 2011), and antioxidant activities (Kang *et al.*, 2009). Verbascoside was included in the present study because of its apparent affinity to the SC and because its structure and physicochemical properties predict that it is a poor permeant (i.e., it serves as a "negative" control for the other three compounds).


An o/w cream and an o/w lotion containing excipients expected to enhance skin penetration (e.g., propylene glycol, glycerol, and the surfactants Tween 60 and Span 60) were formulated to improve permeability of the four selected actives. The concentration of CP was controlled at 10% by weight which has been reported as the maximal concentration of plant ethanolic extracts in topical products without measurable toxicity (Diwan *et al.*, 2001). A secondary objective was to avoid the use of ethanol as this co-solvent may alter the barrier function and irritate the skin. Hispidulin penetrated in the greatest amount followed by vanillic acid and nepetin. Verbascoside was only taken up into the SC and was not percutaneously absorbed. No significant difference was observed between the two formulations, the excipients of which were similar.

The theoretically predicted uptake (determined from the calculated  $J_{\max}$  values determined in the preliminary study (Thitilertdecha *et al.*, 2014)) can be qualitatively compared with the experimental data in Table II. Verbascoside's poor permeability was as anticipated (predicted uptake of only 0.003 nmol·cm<sup>-2</sup>). Vanillic acid was indeed well-absorbed but its penetration was much lower than that expected from the predicted  $J_{\max}$  (440 nmol·cm<sup>-2</sup>). This is most likely because the formulations contained vanillic acid at much less than its saturation concentration. The same conclusion fits with

the results for nepetin and hispidulin, the experimental absorption of which was lower than that predicted from their calculated  $J_{\max}$  values (1.2 and 2.4 nmol·cm<sup>-2</sup>, respectively).

Although delivery of the compounds from the CP cream and lotion were less than those predicted from saturated solution, the percentage penetration observed (Table II) was greater than that from the hydroalcoholic solution used in the preliminary study (Thitilertdecha *et al.*, 2014). This may be due to the presence of surfactants in the cream and lotion formulations facilitating the solubilisation of the compounds in the SC.

The *in vivo* and *in vitro* SC uptake data are compared in Figure 3 and show good overall agreement. SC uptake *in vitro* was generally higher than *in vivo* and statistically significant differences were found for nepetin and hispidulin ( $P < 0.01$  and  $< 0.001$ , respectively). Verbascoside taken up into the SC never reached the analytical LOQ *in vivo*. Thus, while quantitative extrapolation from *in vitro* results to the *in vivo* situation may not be possible, it appears that *in vitro* experiments would be useful for formulation development.



**Figure 3:** Amounts (mean  $\pm$  SD) of vanillic acid, verbascoside, nepetin and hispidulin taken up into the SC from cream and lotion formulations *in vitro* and *in vivo* (filled and open bars, respectively;  $n = 6$ ).



291 The cream and lotion bases without plant extracts were stable for at least 1 month under  
292 accelerated conditions at 30°C and 75%RH (as recommended for Thailand by the World Health  
293 Organization). These stability tests were conducted at the Center of Applied Thai Traditional  
294 Medicine, Faculty of Medicine Siriraj Hospital in Thailand. However, the formulations containing the  
295 plant extracts were unstable under the same stress conditions. The plant extracts in the lotion  
296 separated more easily from the base than in the cream. Nevertheless, the separation was reversible  
297 upon shaking. Formulation reproducibility was shown by consistent viscosity profiles between  
298 different batches of the two formulations.

299

## Conclusion

This is the first investigation of the topical delivery of products containing extracts of *C. petasites* *in vitro* and *in vivo* in humans. Four naturally-occurring active compounds in the plant, vanillic acid, verbascoside, nepetin and hispidulin, were identified as relevant actives for skin permeation studies. The four compounds, based on their uptake and penetration into the skin, together with their known biological activities, may be considered as feasible candidates for the development of novel and effective antimicrobial, anti-inflammatory, and antioxidant formulations and support the ethnomedical uses of *C. petasites* in Thailand. It was also found that the *in vitro* model and the tape-stripping method were robust and effective to establish guidelines for topical delivery studies of natural products. Both lotion and cream formulations containing *C. petasites* extracts are potential standardised medicines for the Thai market, but show some stability problems, that require further development. Overall, this study demonstrates a feasible approach to developing a series of topical medicines that retain the herbal ingredients that many patients value whilst achieving higher levels of standardisation and quality than currently exist on the market.

## Acknowledgement

This study was supported financially by Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand. The plant materials were kindly supplied by the Center of Applied Thai Traditional Medicine from the same university. The authors thank Assoc. Prof. Tawee Laohapand, Assoc. Prof. Pravit Akarasereenont, Ms. Sarah Cordery, Ms. Jantane Wattanarangsang, Ms. Poorada Booncharoen, Ms. Tanta Jongputtharaksa, and Ms. Santhitaporn Klingthong for their support and advice on various aspects of this work.

## 322 References

- 323 Alberti, I., Kalia, Y. N., Naik, A., Bonny, J. D. and Guy, R. H., 2001. *In vivo* assessment of  
324 enhanced topical delivery of terbinafine to human stratum corneum. *J Control Release*. 71, 319-327.
- 325 Clavin, M., Gorzalczany, S., Macho, A., Munoz, E., Ferraro, G., Acevedo, C. and Martino, V.,  
326 2007. Anti-inflammatory activity of flavonoids from *Eupatorium arnottianum*. *J Ethnopharmacol*.  
327 112, 585-589.
- 328 Delaquis, P., Stanich, K. and Toivonen, P., 2005. Effect of pH on the inhibition of *Listeria* spp.  
329 by vanillin and vanillic acid. *J Food Prot*. 68, 1472-1476.
- 330 Diwan, P. V. R., Sitaramam, B. S., Ramakrishna, S. and Ranghavan, K. V., inventors; Counsel of  
331 Scientific and Industrial Research, assignee, 2001. Herbal formulation useful as a therapeutic and  
332 cosmetic applications for the treatment of general skin disorders. USA patent US6200570.
- 333 Gil, B., Sanz, M. J., Terencio, M. C., Ferrandiz, M. L., Bustos, G., Paya, M., Gunasegaran, R.  
334 and Alcaraz, M. J., 1994. Effects of flavonoids on *Naja naja* and human recombinant synovial  
335 phospholipases A<sub>2</sub> and inflammatory responses in mice. *Life Sci*. 54, PL333-338.
- 336 Hazekamp, A., Verpoorte, R., Panthong, A., Hazekamp, A., Verpoorte, R. and Panthong, A.,  
337 2001. Isolation of a bronchodilator flavonoid from the Thai medicinal plant *Clerodendrum petasites*. *J*  
338 *Ethnopharmacol*. 78, 45-49.
- 339 Herkenne, C., Naik, A., Kalia, Y. N., Hadgraft, J. and Guy, R. H., 2007. Ibuprofen transport into  
340 and through skin from topical formulations: *in vitro-in vivo* comparison. *J Invest Dermatol*. 127, 135-  
341 142.
- 342 Kang, K. S., Tanaka, T., Cho, E. J. and Yokozawa, T., 2009. Evaluation of the peroxynitrite  
343 scavenging activity of heat-processed ginseng. *J Med Food*. 12, 124-130.
- 344 Kim, M. C., Kim, S. J., Kim, D. S., Jeon, Y. D., Park, S. J., Lee, H. S., Um, J. Y. and Hong, S. H.,  
345 2011. Vanillic acid inhibits inflammatory mediators by suppressing NF-kappaB in lipopolysaccharide-  
346 stimulated mouse peritoneal macrophages. *Immunopharmacol Immunotoxicol*. 33, 525-532.
- 347 Klaiklay, S., 2009. Chemical constituents from the twigs of *Garcinia hombroniana*, the leaves  
348 of *Garcinia prainiana* and the roots of *Clerodendrum petasites* S. Moore. MSc. Thesis. Thailand,  
349 Prince of Songkla University.
- 350 N'Dri-Stempfer, B., Navidi, W. C., Guy, R. H. and Bunge, A. L., 2009. Improved bioequivalence  
351 assessment of topical dermatological drug products using dermatopharmacokinetics. *Pharm Res*. 26,  
352 316-328.
- 353 Panthong, A., Kanjanapothi, D., Taesotikul, T., Wongcome, T. and Reutrakul, V., 2003. Anti-  
354 inflammatory and antipyretic properties of *Clerodendrum petasites* S. Moore. *J Ethnopharmacol*. 85,  
355 151-156.
- 356 Panthong, A., Kanjanapothi, D. and Taylor, W., 1986. Ethnobotanical review of medicinal  
357 plants from Thai traditional books, Part I: Plants with anti-inflammatory, anti-asthmatic and  
358 antihypertensive properties. *J Ethnopharmacol*. 18, 213-228.
- 359 Pongboonrot, S., 1965. Foreign-Thai medicine and materia medica. Kasem Bannakij,  
360 Bangkok, Thailand.
- 361 Singharachai, C., Palanuvej, C., Kiyohara, H., Yamada, H. and Ruangrungsi, N., 2011.  
362 Pharmacognostic specification of five root species in Thai traditional medicine remedy: Ben-Cha-Lo-  
363 Ka-Wi-Chian. *Phcog J*. 3, 1-11.

364 Sultana, N. and Afolayan, A. J., 2007. A novel daucosterol derivative and antibacterial activity  
365 of compounds from *Arctotis arctotoides*. Nat Prod Res. 21, 889-896.

366 Thai traditional medical textbook: Paet-Ta-Ya-Saat-Song-Kror 2007. conservative ed. The  
367 Rehabilitation Foundation for Thai Traditional Medicine and Ayurved Thamrong School, Bangkok,  
368 Thailand.

369 Thitilertdecha, P., Guy, R. H. and Rowan, M. G., 2014. Characterisation of polyphenolic  
370 compounds in *Clerodendrum petasites* S. Moore and their potential for topical delivery through the  
371 skin. J Ethnopharmacol. 154, 400-407.

372 Thongchai, W., Liawruangrath, B. and Liawruangrath, S., 2007. High-performance liquid  
373 chromatographic determination of arbutin in skin-whitening creams and medicinal plant extracts. J  
374 Cosmet Sci. 58, 35-44.

375 Wagner, H., Kostka, K. H., Lehr, C. M. and Schaefer, U. F., 2000. Drug distribution in human  
376 skin using two different *in vitro* test systems: comparison with *in vivo* data. Pharm Res. 17, 1475-  
377 1481.

378